ANTHRACYCLINE-INDUCED CARDIAC TOXICITY
Clinical trials for ANTHRACYCLINE-INDUCED CARDIAC TOXICITY explained in plain language.
Never miss a new study
Get alerted when new ANTHRACYCLINE-INDUCED CARDIAC TOXICITY trials appear
Sign up with your email to follow new studies for ANTHRACYCLINE-INDUCED CARDIAC TOXICITY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Arm cuff trick may shield heart during chemo
Disease control Recruiting nowThis study tests whether a non-invasive procedure called remote ischemic preconditioning (RIPC) can prevent heart damage in lymphoma patients receiving anthracycline chemotherapy. About 608 adults with lymphoma or breast cancer will be randomly assigned to receive either RIPC or …
Matched conditions: ANTHRACYCLINE-INDUCED CARDIAC TOXICITY
Phase: NA • Sponsor: Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III • Aim: Disease control
Last updated May 16, 2026 22:31 UTC
-
Heart shield: diabetes drug may prevent Chemo-Induced cardiac damage
Prevention Recruiting nowThis study tests whether dapagliflozin, a drug used for diabetes, can prevent heart damage caused by anthracycline chemotherapy in breast cancer patients. About 100 women will receive either dapagliflozin or a placebo daily during their chemo. Researchers will monitor heart funct…
Matched conditions: ANTHRACYCLINE-INDUCED CARDIAC TOXICITY
Phase: PHASE2 • Sponsor: University Medical Centre Ljubljana • Aim: Prevention
Last updated May 16, 2026 22:33 UTC